Soo Yong Tan

Tan Soo Yong

Appointment(s)
  • Associate Professor, Department of Pathology
Administrative Appointment(s)
  • Head, Department of Pathology, NUS Yong Loo Lin School of Medicine
  • Chief, Department of Pathology, National University Health System
Joint Appointment(s)
  • Senior Principal Investigator, Institute of Cell and Molecular Biology, A*STAR
  • Head, Advanced Molecular Pathology Laboratory, Institute of Cell and Molecular Biology, A*STAR
  • Visiting Professor, University Malaya, Malaysia
  • Visiting Professor, Guangdong Academy of Medical Sciences and Guangdong Hospital, China
  • Senior Consultant, Regulatory Policy and Licensing Division, Ministry of Health, Singapore
  • Senior Consultant, Manpower Development and Professional Standards Division, Ministry of Health, Singapore
  • Visiting Consultant, Division of Medical Sciences, National Cancer Centre, Singapore
  • Visiting Consultant, National Skin Centre, Singapore
  • Singapore Representative to the Advisory Board of the IAEA
  • Consultant, Johnson & Johnson, Inc.
  • Consultant, Abbott Molecular
  • Key Opinion Leader, Ventana, USA
  • Chairman, Biobanking Subcommittee, Asian Network of Research Resource Centres
  • Member, Diagnostic Hotspot Advisory Panel, Exploit Technologies, A*STAR
  • Member, Advisory Group on the Sharing of Research Data, Biomedical Research Council
  • Member, Advisory Board, Roche-Ventana
  • Member, Advisory Board, MiRXES
  • Member, Hub Evaluation Panel, Diagnostic Hub, ETPL
  • International Advisor (West Pacific), Royal College of Pathologists
  • Member, International Lymphoma Study Group
Academic Qualifications
  • DPhil (Oxon), Oxford University, United Kingdom
  • MBBS, National University of Singapore, Singapore
  • MRCPath, Royal College of Pathologists, United Kingdom
  • FRCPath, Royal College of Pathologists, United Kingdom
  • DMJ (Pathology), Society of Apothecaries of London, United Kingdom
  • DipRCPath, Royal College of Pathologists, United Kingdom
Research Interest(s)
  • Haematopathology
  • Haematology Oncology
  • Lymphoma
  • Leukaemia
Recent Publications
  • 1. Ng SB, Chung T-H, Kato S, Nakamura S, Takahashi E, Ko YH, Khoury JD, Yin CC, Soong R, Jeyasekharan AD et al. 2017 Nov. EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes. Haematologica. doi: 10.3324/haematol.2017.180430.
  • 2. Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, Magdalene KHK, Tan SH, Lange M, Tan SY et al. 2017 Jan. Simultaneous Inhibition of PI3K delta and PI3K alpha Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-kappa B and AKT. Cancer Cell. 31(1):64-78. doi: 10.1016/j.ccell.2016.12.003.
  • 3. Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, Cai QQ, Sim KS, Nairismagi M-L, Laurensia Y et al. 2016 Sep. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncology. 17(9):1240-1247. doi: 10.1016/S1470-2045(16)30148-6.
  • 4. Nairismagi ML, Tan J, Lim JQ, Nagarajan S, Ng CCY, Rajasegaran V, Huang D, Lim WK, Laurensia Y, Wijaya GC et al. 2016 Jun. JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia. 30(6):1311-1319. doi: 10.1038/leu.2016.13.
  • 5. Tan CL, Ong YK, Tan SY, Ng SB. 2016 May. IgG4-positive extranodal marginal zone lymphoma arising in Hashimoto's thyroiditis: clinicopathological and cytogenetic features of a hitherto undescribed condition. Histopathology. 68(6):931-937. doi: 10.1111/his.12854.